According to Theravance Biopharma, the company is selling its stake in Theravance Respiratory Company (TRC), which received royalties from sales of GSK's Trelegy Ellipta fluticasone furoate / umeclidinium / vilanterol DPI. The deal with Royalty Pharma is worth up to $1.5 billion, including $1.1 billion up front, the company said. Theravance Biopharma owns 85% of TRC; … [Read more...] about Theravance, Innoviva selling Trelegy Ellipta royalty interests to Royalty Pharma
News
Glenmark and SaNOtize publish positive results from Phase 3 trial of nitric oxide nasal spray for COVID-19
Glenmark Pharmaceuticals and SaNOtize have announced the publication of results from a Phase 3 clinical trial of NONS nitric oxide nasal spray for the treatment of COVID-19 in The Lancet Regional Health Southeast Asia. SaNOtize announced initiation of the Phase 3 trial in June 2021, and Glenmark announced in August 2021 that it had acquired the rights to NONS in India … [Read more...] about Glenmark and SaNOtize publish positive results from Phase 3 trial of nitric oxide nasal spray for COVID-19
Pulmatrix initiates Phase 1 trial of PUR3100 inhaled dry powder DHE
Pulmatrix said that the first subjects have been dosed in a Phase 1 trial of the company's PUR3100 dry powder dihydroergotamine (DHE), which is based on Pulmatrix's iSPERSE particle engineering platform. The company announced in March 2021 that it intended to develop the PUR3100 DPI for the treatment of migraines. The Phase 1 trial is expected to enroll 24 healthy … [Read more...] about Pulmatrix initiates Phase 1 trial of PUR3100 inhaled dry powder DHE
NurExone partners with Polyrizon for development of intranasal therapy for spinal cord injuries
Israeli startup NurExone Biologic has announced that it will pay Israeli nasal delivery specialist Polyrizon a total of up to $3,350,000 for development of an intranasal formulation of NurExone's ExoTherapy, exosomes loaded with modified siRNA sequences for the treatment of traumatic spinal cord injuries. The formulation will be based on Polyrizon's Trap and Target … [Read more...] about NurExone partners with Polyrizon for development of intranasal therapy for spinal cord injuries
Bayer launches Astepro Allergy nasal spray in the US
Bayer said that its Astepro Allergy azelastine nasal spray is now available over the counter in US retail stores for the treatment of respiratory allergy symptoms in people aged 6 and older. The FDA approved Astepro Allergy for nonprescription use in June 2021. Bayer Consumer Health US VP and General Manager of Upper Respiratory Catherine Vennat said, "At Bayer, … [Read more...] about Bayer launches Astepro Allergy nasal spray in the US
RS BioTherapeutics reports positive preclinical results for its inhaled CBDa
US-based startup RS BioTherapeutics has announced that a proof of concept study demonstrated that its RSBT-001 semi-synthetic cannabidiolic acid (CBDa) reduced but did not eliminate cytokines when dosed intranasally at 1 mg/kg in a mouse model of pulmonary inflammation. The study was conducted by researchers at Marshall University. RS BioTherapeutics licensed the … [Read more...] about RS BioTherapeutics reports positive preclinical results for its inhaled CBDa
Meissa Vaccines names Frank Glavin as CEO
Intranasal vaccine developer Meissa Vaccines has announced that Martin Moore is stepping down as the company's CEO and Frank Glavin has joined the company as the new Chief Executive Officer. Moore will stay with Meissa as Chief Scientific Officer. Glavin was most recently CEO of Orphan Technologies and was previously Head of Neovii Biotech North America. Meissa … [Read more...] about Meissa Vaccines names Frank Glavin as CEO
FDA approves Beyond Air’s LungFit PH inhaled NO system for PPHN
According to Beyond Air, the FDA has approved the company's LungFit PH inhaled nitric oxide (iNO) generation and delivery system for the treatment of babies with persistent pulmonary hypertension of the newborn (PPHN). The approval is the first for the company, which is also developing LungFit iNO systems for the treatment of COVID-19 pneumonia, bronchiolitis, and … [Read more...] about FDA approves Beyond Air’s LungFit PH inhaled NO system for PPHN
Cessatech announces plans for pivotal trial of CT001 intranasal analgesic
Danish startup Cessatech, a spin out from Rigshospitalet, announced that it has gotten the go-ahead for a pivotal trial of its CT001 analgesic nasal spray. Cessatech is developing CT001, a fixed dose combination of sufentanil and ketamine, for use in pediatric patients and has already completed dosing in a Phase 2 PK study of the nasal spray in children aged 1-17. … [Read more...] about Cessatech announces plans for pivotal trial of CT001 intranasal analgesic
DFE launches Lactohale 400 anhydrous inhalation grade lactose
DFE Pharma has announced the launch of a new product in its range of Lactohale inhalation grade lactose products; Lactohale 400 milled anhydrous lactose is described as a grade for formulations "where a relatively good flow with some cohesiveness is required." According to the company, the median particle size of Lactohale 400 is 100μm, and DFE Pharma will work with … [Read more...] about DFE launches Lactohale 400 anhydrous inhalation grade lactose